PMID- 20079548
OWN - NLM
STAT- MEDLINE
DCOM- 20100601
LR  - 20211020
IS  - 1879-3096 (Electronic)
IS  - 0167-7799 (Print)
IS  - 0167-7799 (Linking)
VI  - 28
IP  - 4
DP  - 2010 Apr
TI  - Frontiers in cancer nanomedicine: directing mass transport through biological 
      barriers.
PG  - 181-8
LID - 10.1016/j.tibtech.2009.12.007 [doi]
AB  - The physics of mass transport within body compartments and across biological 
      barriers differentiates cancers from healthy tissues. Variants of nanoparticles 
      can be manufactured in combinatorially large sets, varying by only one 
      transport-affecting design parameter at a time. Nanoparticles can also be used as 
      building blocks for systems that perform sequences of coordinated actions, in 
      accordance with a prescribed logic. We refer to these as Logic-Embedded Vectors 
      (LEVs). Nanoparticles and LEVs are ideal probes for the determination of mass 
      transport laws in tumors, acting as imaging contrast enhancers, and can be 
      employed for lesion-selective delivery of therapy. Their size, shape, density and 
      surface chemistry dominate convective transport in the bloodstream, margination, 
      cell adhesion, selective cellular uptake, as well as sub-cellular trafficking and 
      localization. As argued here, the understanding of transport differentials in 
      cancer, termed 'transport oncophysics', reveals a promising new frontier in 
      oncology: the development of lesion-specific delivery particulates that exploit 
      mass transport differentials to deploy treatment of greater efficacy and reduced 
      side effects.
CI  - 2009 Elsevier Ltd. All rights reserved.
FAU - Ferrari, Mauro
AU  - Ferrari M
AD  - University of Texas Health Science Center at Houston (UTHSC-H), Department of 
      NanoMedicine and Biomedical Engineering, 1825 Pressler, Suite 537, Houston, TX 
      77030, USA. Mauro.Ferrari@uth.tmc.edu
LA  - eng
GR  - U54 CA143837-01/CA/NCI NIH HHS/United States
GR  - R01CA128797/CA/NCI NIH HHS/United States
GR  - R01 CA128797-03/CA/NCI NIH HHS/United States
GR  - RC2 GM092599-01/GM/NIGMS NIH HHS/United States
GR  - U54 CA143837/CA/NCI NIH HHS/United States
GR  - U54CA143837/CA/NCI NIH HHS/United States
GR  - R33 CA122864-03/CA/NCI NIH HHS/United States
GR  - R01 CA128797/CA/NCI NIH HHS/United States
GR  - R33 CA122864/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
DEP - 20100114
PL  - England
TA  - Trends Biotechnol
JT  - Trends in biotechnology
JID - 8310903
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Antineoplastic Agents/*pharmacokinetics/*therapeutic use
MH  - Humans
MH  - Nanomedicine/*methods
MH  - Nanoparticles/*therapeutic use
MH  - Neoplasms/*drug therapy
PMC - PMC2843761
MID - NIHMS167462
EDAT- 2010/01/19 06:00
MHDA- 2010/06/02 06:00
PMCR- 2011/04/01
CRDT- 2010/01/19 06:00
PHST- 2009/11/09 00:00 [received]
PHST- 2009/12/16 00:00 [revised]
PHST- 2009/12/17 00:00 [accepted]
PHST- 2010/01/19 06:00 [entrez]
PHST- 2010/01/19 06:00 [pubmed]
PHST- 2010/06/02 06:00 [medline]
PHST- 2011/04/01 00:00 [pmc-release]
AID - S0167-7799(09)00240-6 [pii]
AID - 10.1016/j.tibtech.2009.12.007 [doi]
PST - ppublish
SO  - Trends Biotechnol. 2010 Apr;28(4):181-8. doi: 10.1016/j.tibtech.2009.12.007. Epub 
      2010 Jan 14.